Today we are happy to unveil our proposed company name change to Vivesto!

We will be holding a presentation for more information, watch here from 14:00 CET: https://youtu.be/SVqz40v8Wkw

#biotech #oncology

https://www.oasmia.com/en/oasmia-announces-intention-to-change-its-name-to-vivesto/

Today we announced plans to raise ~SEK150 million in a rights issue to strengthen our balance sheet and help us achieve our short to medium term business objectives.

https://www.oasmia.com/en/oasmia-resolves-on-a-fully-secured-rights-issue-of-approximately-sek-151-million/

#biotech #oncology

Oasmia is proud to have developed and secured the approval of Apealea® in Europe for the treatment of first relapse ovarian cancer. It will be launched in Europe by Inceptua, one of our marketing partners, during this year. 2022 is shaping up to be an exciting year!

#oncology

Happy New Year from Oasmia! We are looking forward to a productive year, continuing our mission our mission to build a diversified pipeline focused on hard-to-treat and late-stage cancers using different mechanisms of action.

#biotech #oncology